- Home
- SBFM vs OGEN Comparison
SBFM vs OGEN Comparison
Compare SBFM & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- OGEN
- Stock Information
- Founded
- SBFM 2006
- OGEN 1996
- Country
- SBFM United States
- OGEN United States
- Employees
- SBFM N/A
- OGEN N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- OGEN Health Care
- Exchange
- SBFM Nasdaq
- OGEN Nasdaq
- Market Cap
- SBFM 6.7M
- OGEN 5.4M
- IPO Year
- SBFM N/A
- OGEN N/A
- Fundamental
- Price
- SBFM $1.75
- OGEN $1.37
- Analyst Decision
- SBFM Strong Buy
- OGEN
- Analyst Count
- SBFM 1
- OGEN 0
- Target Price
- SBFM $7.00
- OGEN N/A
- AVG Volume (30 Days)
- SBFM 71.9K
- OGEN 242.1K
- Earning Date
- SBFM 11-04-2025
- OGEN 11-12-2025
- Dividend Yield
- SBFM N/A
- OGEN N/A
- EPS Growth
- SBFM N/A
- OGEN N/A
- EPS
- SBFM N/A
- OGEN N/A
- Revenue
- SBFM $36,341,741.00
- OGEN N/A
- Revenue This Year
- SBFM $32.20
- OGEN N/A
- Revenue Next Year
- SBFM $32.74
- OGEN N/A
- P/E Ratio
- SBFM N/A
- OGEN N/A
- Revenue Growth
- SBFM 19.22
- OGEN N/A
- 52 Week Low
- SBFM $1.17
- OGEN $1.01
- 52 Week High
- SBFM $3.90
- OGEN $18.90
- Technical
- Relative Strength Index (RSI)
- SBFM 66.08
- OGEN 55.65
- Support Level
- SBFM $1.50
- OGEN $1.27
- Resistance Level
- SBFM $1.74
- OGEN $1.45
- Average True Range (ATR)
- SBFM 0.09
- OGEN 0.09
- MACD
- SBFM 0.01
- OGEN 0.00
- Stochastic Oscillator
- SBFM 96.84
- OGEN 61.90
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.